Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 16, 2021

SELL
$4.87 - $17.29 $44,920 - $159,482
-9,224 Closed
0 $0
Q3 2020

Jun 26, 2023

BUY
$15.08 - $27.04 $139,097 - $249,416
9,224 New
9,224 $151,000
Q2 2020

Jun 26, 2023

BUY
$14.57 - $23.96 $134,393 - $221,007
9,224 New
9,224 $215,000
Q1 2020

Jul 12, 2023

BUY
$10.27 - $21.23 $94,730 - $195,825
9,224 New
9,224 $136,000
Q1 2020

Mar 30, 2023

BUY
$10.27 - $21.23 $22,090 - $45,665
2,151 Added 30.41%
9,224 $136,000
Q1 2020

May 15, 2020

BUY
$10.27 - $21.23 $22,090 - $45,665
2,151 Added 30.41%
9,224 $137,000
Q4 2019

Jul 12, 2023

BUY
$8.36 - $23.81 $59,130 - $168,408
7,073 New
7,073 $144,000
Q3 2019

Jul 12, 2023

BUY
$9.83 - $14.82 $69,527 - $104,821
7,073 New
7,073 $69,000
Q2 2019

Jul 12, 2023

BUY
$12.9 - $20.8 $91,241 - $147,118
7,073 New
7,073 $95,000
Q1 2019

Jul 13, 2023

BUY
$17.7 - $24.93 $125,192 - $176,329
7,073 New
7,073 $139,000
Q1 2019

Mar 30, 2023

BUY
$17.7 - $24.93 $125,192 - $176,329
7,073 New
7,073 $139,000
Q1 2019

May 16, 2019

SELL
$17.7 - $24.93 $345,946 - $487,256
-19,545 Reduced 73.43%
7,073 $139,000
Q1 2019

May 15, 2019

BUY
$17.7 - $24.93 $345,946 - $487,256
19,545 Added 276.33%
26,618 $761,000
Q4 2018

Jul 13, 2023

BUY
$19.05 - $36.45 $134,740 - $257,810
7,073 New
7,073 $159,000
Q4 2018

Feb 14, 2019

BUY
$19.05 - $36.45 $105,232 - $201,349
5,524 Added 356.62%
7,073 $160,000
Q3 2018

Jul 13, 2023

BUY
$34.41 - $44.23 $243,381 - $312,838
7,073 New
7,073 $263 Million
Q3 2018

Nov 14, 2018

SELL
$34.41 - $44.23 $128,314 - $164,933
-3,729 Reduced 70.65%
1,549 $58,000
Q4 2017

Feb 15, 2018

SELL
$28.58 - $49.91 $147,272 - $257,186
-5,153 Reduced 49.4%
5,278 $239,000
Q2 2017

Aug 14, 2017

BUY
N/A
10,431
10,431 $215,000

Others Institutions Holding ASMB

# of Institutions
1
Shares Held
16.3K
Call Options Held
0
Put Options Held
0

About ASSEMBLY BIOSCIENCES, INC.


  • Ticker ASMB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,436,900
  • Market Cap $822M
  • Description
  • Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...
More about ASMB
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.